Introduction

Recent CDC surveillance shows a sharp rise in Candida auris, a drug‑resistant yeast, across American hospitals. Reported cases climbed from 2,882 in 2022 to 6,197 in 2024, more than doubling the burden within three years. This surge highlights the need for vigilant infection‑control practices, improved screening, and ongoing attention to antifungal resistance.

Growth of Clinical and Screening Cases

Both clinical infections (identified while treating a suspected illness) and screening detections (found by swabbing patients for colonization) rose steeply. Screening became nationally notifiable in 2023, which added to the count independent of actual transmission. Bloodstream infections, the most reliable indicator of invasive disease, increased by about 60 %—from 991 cases in 2022 to 1,586 in 2024—while all clinical cases more than doubled, showing that many additional cases involve non‑blood specimens such as urine, wounds, and respiratory samples.

Changing Screening Practices

During the early years, long‑term acute care hospitals accounted for the majority of screening detections. By 2024, ordinary acute‑care hospitals performed more than half of the screenings, reflecting a shift toward admission‑time testing that captures carriers arriving from other facilities. This broader approach helps locate colonized patients before they can spread the fungus to roommates or equipment.

Patient Demographics and Risk Factors

Nearly nine in ten affected individuals are aged 45 or older, and 61 % are men. Common risk factors include extended hospital stays, use of ventilators, central lines, and heavy antibiotic exposure. These characteristics have remained consistent, underscoring the vulnerability of seriously ill patients.

Impact of the Pandemic and Current Trends

The COVID‑19 pandemic strained staffing, supplies, and routine hygiene, allowing Candida auris to spread more widely. Since that period, the year‑over‑year growth rate has slowed—from a 96 % jump between 2021‑2022 to 54 % and then 40 % in later years—suggesting that restored infection‑control measures are beginning to take effect.

Antifungal Resistance Concerns

Most isolates already resist fluconazole, a frontline antifungal, and there is growing concern about strains that also defeat echinocandins. While the surveillance data do not include susceptibility results, the potential emergence of pan‑resistant strains remains a critical public‑health warning.

Conclusion

The doubling of Candida auris cases underscores the importance of sustained screening, strict hygiene, and targeted isolation of colonized patients. As hospitals continue to refine detection methods and reinforce infection‑control protocols, the slowdown in case growth offers a hopeful sign. Ongoing surveillance and research into antifungal resistance will be essential to keep this dangerous fungus in check and protect the most vulnerable patients.